查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1925086

全球神經發育障礙數位療法市場預測（至2032年），按產品類型、殘疾類型、最終用戶和地區分類

Digital Therapeutics for Neurodevelopmental Disorders Market Forecasts to 2032 - Global Analysis By Product Type, Disorder Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球用於治療神經發育障礙的數位療法市場價值將達到 4,800 萬美元，預計到 2032 年將達到 2.0444 億美元。

預計在預測期內，針對神經發育障礙的數位療法將以23.0%的複合年成長率成長。這些數位療法利用技術手段，幫助患有注意力不足過動症（ADHD）、自閉症和學習障礙等疾病的個體改善行為、認知和情緒調節能力。這些檢驗的數位工具透過行動應用程式、虛擬實境體驗和遊戲化練習提供個人化干涉，從而實現持續評估和即時回饋。它們與傳統治療方法相輔相成，提高了患者的參與度，並提供靈活且便利的遠距醫療服務。這些解決方案在診所和家庭中的日益普及，正在改善早期治療、提高治療依從性和整體治療效果，並提供數據驅動的指導，從而改變神經發育障礙的有效監測和管理方式。

一項針對 31 項研究（涉及 2169 名患有 ADHD 的兒童和青少年）進行的Meta分析發現，與對照組相比，數位治療性介入顯著改善了注意力不集中症狀和反應時間，以及執行功能和工作記憶，表明其具有潛在的臨床效用。

提高看護者和臨床醫生的意識和接受度

家長、看護者和醫療專業人員對數位療法的理解和接受度不斷提高，正在推動市場成長。臨床試驗證據和積極的患者療效增強了人們對這些干預措施的信心。看護者重視便利、遠距和高效的治療方案，臨床醫師則將其視為標準療法的寶貴補充。醫療服務提供者日益成長的信任和支持正在推動數位療法的應用，並刺激進一步的研發，從而促進基於技術的神經發育障礙治療方法的廣泛應用，並推動市場擴張。

臨床檢驗有限和監管方面的挑戰

限制神經發育障礙數位療法發展的主要挑戰在於缺乏長期臨床證據和監管路徑不明朗。許多解決方案的檢驗有限，導致醫療專業人員在推薦時持謹慎態度。各國監管政策的不一致造成了核准、報銷政策和法律合規的不確定性。由於臨床醫生優先考慮已確立的、經臨床驗證的治療方法，數位替代療法的普及速度仍然緩慢。此外，缺乏標準化的評估方法也降低了人們對治療結果的信心。這些監管和檢驗的不足延緩了商業化進程，並限制了數位治療方法在傳統醫療體系中的廣泛應用。

擴展遠端醫療和遠距護理模式

遠端醫療和虛擬照護的日益普及為神經發育障礙管理領域的數位療法創造了強勁的成長機會。數位平台使治療能夠在醫院之外進行，讓患者在家中即可接受個人化介入。這種模式支持持續監測、早期診斷和長期治療，同時最大限度地減少了出行和基礎設施的限制。醫療服務的改善惠及農村和醫療資源匱乏地區，擴大了市場覆蓋範圍。隨著遠距醫療的普及，數位療法可以輕鬆整合到遠距醫療框架中，從而推動更廣泛的應用，並加強神經發育障礙的長期照護策略。

來自傳統療法和替代療法的競爭

數位療法面臨的主要威脅之一是傳統療法的主導地位，例如行為療法和藥物治療，這些療法已被廣泛信任並被常規使用。由於多年的臨床檢驗和成熟的治療路徑，醫護人員和看護者往往更傾向於面對面的治療方法。替代療法和輔助療法的存在進一步加劇了這種壓力，使得數位解決方案難以被接受。這種激烈的競爭可能會限制數位療法的普及率，降低患者的轉換意願，並減緩數位療法在神經發育障礙治療領域的整體發展。

新冠疫情的影響：

新冠疫情的爆發對神經發育障礙的數位療法市場產生了顯著的正面影響，促使治療模式轉向遠端解決方案。人際接觸的限制擾亂了傳統的治療服務，使得居家和虛擬治療方案的需求變得迫切。在長期封鎖期間，數位療法成為維持治療流程、追蹤患者進度和支持看護者的有效手段。人們對心理和發育健康的日益關注進一步促進了技術主導治療的普及。疫情加速了數位療法的應用，增加了資金籌措，並提高了監管的柔軟性，從而鞏固了數位療法在未來神經發育障礙管理中的關鍵作用。

預計在預測期內，行動應用領域將佔據最大的市場佔有率。

由於行動應用具有高度便利性和廣泛的普及性，預計在預測期內，行動應用領域將佔據最大的市場佔有率。這些解決方案專為主流智慧型手機和平板電腦設計，提供以行為、認知和情感發展為重點的個人化治療活動。其使用者友善性使得兒童、看護者和臨床醫生能夠在傳統醫療機構之外繼續進行治療。行動應用還支援持續的進度追蹤和遠端監督，從而增強治療的連續性。憑藉其簡潔性、適應性和高用戶參與度，行動應用比更複雜的技術更受歡迎，鞏固了主導地位。

預計在預測期內，患者群體將在神經發育障礙領域中實現最高的複合年成長率。

在預測期內，患者群體預計將成為神經發育障礙領域中成長最快的群體，這主要得益於患者能夠更便捷地直接參與技術賦能的治療方案。智慧型手機和數位平台的普及使得患者能夠在傳統醫療機構之外積極參與治療。互動式、個人化的治療內容能夠提高患者的參與度和長期依從性。隨著患者賦能和居家照護的重要性日益凸顯，對便利且靈活的數位化治療方案的需求持續成長。公眾意識的提高、對數位健康工具的日益親和性以及對個人化護理模式的關注，正在加速數位化治療方案的普及，使患者群體成為最具成長潛力的領域。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療保健體系和數位健康技術的快速應用。智慧型設備的普及率高、遠距遠端醫療框架完善以及醫療專業人員的高度認知，正在推動數位療法的廣泛應用。有利的政策支持、持續的創新以及對兒童和精神健康解決方案的大量投資，都鞏固了該地區的主導地位。對早期療育和個人化醫療的重視，進一步推動了數位療法的應用。這些因素共同造就了北美強大的市場地位和持續的領先優勢，使其成為全球神經發育護理領域數位療法應用的最大貢獻者。

預計年複合成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率，這主要得益於數位化普及和醫療保健現代化進程的加速。行動裝置的普及和網路連線的增強，使得基於應用程式和遠端醫療解決方案的取得更加便捷。人們對發展障礙的認知不斷提高，加上相關數位健康計畫的推廣，正在推動看護者和醫療保健提供者採用這些解決方案。該地區大規模的兒童人口以及對經濟實惠且擴充性的護理解決方案的需求，進一步推動了數位療法的市場成長。這些因素共同作用，使亞太地區成為數位療法成長最快的市場。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測以及複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球神經發育障礙數位療法市場（按產品類型分類）

  • 行動應用
  • 軟體平台
  • 基於虛擬實境（VR）的治療方法
  • 穿戴式整合解決方案

6. 全球神經發育障礙數位療法市場（依疾病類型分類）

  • 注意力不足過動症（ADHD）
  • 泛自閉症障礙（ASD）
  • 閱讀障礙與學習障礙
  • 其他類型的故障

7. 全球神經發育障礙數位療法市場（以最終用戶分類）

  • 病人
  • 看護者
  • 醫療保健提供者
  • 付款方/保險公司

8. 全球神經發育障礙數位療法市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：企業概況

  • Akili Interactive Labs
  • Cognoa
  • NeuroSigma
  • Atenxia
  • Braingaze
  • Tali Digital
  • Neurotech International
  • Sincrolab
  • Poppins
  • Limbix
  • Floreo
  • Rethink Autism
  • Elemy
  • Mightier
  • Revibe Technologies
Product Code: SMRC33480

According to Stratistics MRC, the Global Digital Therapeutics for Neurodevelopmental Disorders Market is accounted for $48.0 million in 2025 and is expected to reach $204.44 million by 2032 growing at a CAGR of 23.0% during the forecast period. Digital therapeutics designed for neurodevelopmental disorders utilize technology-based programs to support improvements in behavior, cognition, and emotional regulation in individuals with conditions like ADHD, autism, and learning disabilities. These validated digital tools deliver customized interventions via mobile apps, virtual reality experiences, and gamified exercises, allowing continuous assessment and instant feedback. Serving as a complement to conventional therapies, they increase patient participation and provide flexible, remote-accessible care. The rising use of these solutions in clinics and homes is enhancing early treatment, adherence, and overall outcomes, offering data-informed guidance that transforms how neurodevelopmental conditions are monitored and managed effectively.

According to a meta-analysis of 31 studies involving 2,169 children and adolescents with ADHD, digital therapeutic interventions significantly improved inattention symptoms and reaction time while enhancing executive function and working memory compared with control groups, indicating potential clinical benefit.

Market Dynamics:

Driver:

Rising awareness and acceptance among caregivers and clinicians

Increasing knowledge and acceptance of digital therapeutics among parents, caregivers, and medical professionals are boosting market growth. Evidence from clinical trials and successful patient outcomes enhances confidence in these interventions. Caregivers value accessible, remote, and efficient treatment options, while clinicians see them as valuable complements to standard therapies. Rising trust and endorsement by healthcare providers drive adoption and stimulate further R&D, supporting the broader integration of technology-based treatments for neurodevelopment disorders and encouraging market expansion.

Restraint:

Limited clinical validation and regulatory challenges

A significant challenge limiting the growth of digital therapeutics for neurodevelopmental disorders is insufficient long-term clinical evidence and unclear regulatory pathways. Numerous solutions have limited validation, making healthcare professionals cautious about recommending them. Regulatory inconsistencies across countries create uncertainty around approvals, reimbursement policies, and legal compliance. As clinicians prioritize established, clinically proven therapies, adoption of digital alternatives remains slow. Additionally, the lack of standardized assessment methods reduces confidence in treatment outcomes. These regulatory and validation gaps delay commercialization and restrict broader acceptance of digital therapeutics within traditional healthcare systems.

Opportunity:

Expansion of telehealth and remote care models

The growing acceptance of telehealth and virtual care creates strong growth opportunities for digital therapeutics in neurodevelopmental disorder management. Digital platforms enable therapy delivery beyond hospitals, allowing patients to receive personalized interventions at home. This model supports consistent monitoring, early diagnosis, and ongoing treatment while minimizing travel and infrastructure constraints. Improved access benefits rural and underserved communities, expanding market reach. As remote healthcare becomes mainstream, digital therapeutics can integrate easily into telemedicine frameworks, driving broader adoption and strengthening long-term care strategies for neurodevelopmental conditions.

Threat:

Competition from traditional therapies and alternative treatments

A major threat to digital therapeutics is the dominance of traditional treatment methods, including behavioral and pharmacological therapies, which are already trusted and routinely prescribed. Healthcare professionals and caregivers often favor in-person interventions because of long-standing clinical validation and established care pathways. The presence of alternative and complementary therapies adds further pressure, making it challenging for digital solutions to gain acceptance. This strong competition can restrict adoption rates, reduce patient willingness to switch, and slow the overall growth of digital therapeutics in neurodevelopmental disorder care.

Covid-19 Impact:

The outbreak of COVID-19 had a strong positive influence on the digital therapeutics market for neurodevelopmental disorders by shifting care delivery toward remote solutions. Restrictions on physical interactions disrupted traditional therapy services, creating an urgent need for home-based and virtual treatment options. Digital therapeutics emerged as effective tools for maintaining therapy routines, tracking patient progress, and supporting caregivers during extended lockdowns. Increased focus on mental and developmental health further boosted acceptance of technology-driven care. The pandemic prompted faster adoption, higher funding, and greater regulatory openness, reinforcing the role of digital therapeutics as essential components of future neurodevelopmental disorder management.

The mobile applications segment is expected to be the largest during the forecast period

The mobile applications segment is expected to account for the largest market share during the forecast period because they are highly convenient and widely accessible. Designed to run on commonly used smart phones and tablets, these solutions deliver personalized therapeutic activities focused on behavior, cognition, and emotional development. Their user-friendly nature allows children, caregivers, and clinicians to engage consistently with therapy outside traditional care settings. Mobile apps also support ongoing progress tracking and remote supervision, enhancing treatment continuity. Due to their simplicity, adaptability, and strong user engagement, mobile applications are preferred over more complex technologies, securing the leading position within this digital therapeutics market.

The patients segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the patients segment is predicted to witness the highest growth rate for neurodevelopmental disorders as individuals increasingly engage directly with technology-enabled therapy solutions. Easy access to smart phones and digital platforms allows patients to participate actively in their treatment beyond traditional healthcare settings. Interactive and customized therapeutic content enhances engagement and long-term adherence. As patient empowerment and home-based care gain importance, demand for convenient and flexible digital therapies continues to rise. Improved awareness, higher comfort with digital health tools, and a focus on personalized care models are accelerating adoption, positioning patients as the segment with the highest growth potential.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare systems and rapid adoption of digital health technologies. High penetration of smart devices, well-established telemedicine frameworks, and strong clinician awareness drive widespread use of digital therapies. Favorable policy support, continuous innovation, and significant investment in pediatric and mental health solutions contribute to regional leadership. Emphasis on early intervention and personalized care further boosts adoption. These factors collectively enable strong market presence and sustained leadership, making North America the largest contributor to global digital therapeutics adoption in neurodevelopmental care.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by accelerating digital adoption and healthcare modernization. Widespread use of mobile devices and improved connectivity enable broader access to app-based and remote therapeutic solutions. Increasing recognition of developmental disorders, along with supportive digital health programs, is encouraging adoption among caregivers and providers. The region's large pediatric population and need for affordable, scalable care solutions further fuel expansion. These factors collectively position Asia-Pacific as the highest-growth market for digital therapeutics.

Key players in the market

Some of the key players in Digital Therapeutics for Neurodevelopmental Disorders Market include Akili Interactive Labs, Cognoa, NeuroSigma, Atenxia, Braingaze, Tali Digital, Neurotech International, Sincrolab, Poppins, Limbix, Floreo, Rethink Autism, Elemy, Mightier and Revibe Technologies.

Key Developments:

In January 2026, NeuroSigma, Inc. announced the completion of an approximately $1-million investment into a high-volume manufacturing line in partnership with Singapore-based Armstrong Asia. The investment was led by Pasadena-based strategic advisory and investment group Checkmate Capital.

In May 2024, Akili has signed a definitive merger agreement with mental health and fitness company Virtual Therapeutics in a deal reportedly worth $34 million. Under the agreement, which is slated to close in the third quarter of 2024, Akili shareholders will receive $0.4340 per share of common stock in cash.

Product Types Covered:

  • Mobile Applications
  • Software Platforms
  • Virtual Reality (VR)-based Therapies
  • Wearable-integrated Solutions

Disorder Types Covered:

  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Autism Spectrum Disorder (ASD)
  • Dyslexia & Learning Disabilities
  • Other Disorder Types

End Users Covered:

  • Patients
  • Caregivers
  • Healthcare Providers
  • Payers / Insurance Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By Product Type

  • 5.1 Introduction
  • 5.2 Mobile Applications
  • 5.3 Software Platforms
  • 5.4 Virtual Reality (VR)-based Therapies
  • 5.5 Wearable-integrated Solutions

6 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By Disorder Type

  • 6.1 Introduction
  • 6.2 Attention Deficit Hyperactivity Disorder (ADHD)
  • 6.3 Autism Spectrum Disorder (ASD)
  • 6.4 Dyslexia & Learning Disabilities
  • 6.5 Other Disorder Types

7 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By End User

  • 7.1 Introduction
  • 7.2 Patients
  • 7.3 Caregivers
  • 7.4 Healthcare Providers
  • 7.5 Payers / Insurance Companies

8 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Akili Interactive Labs
  • 10.2 Cognoa
  • 10.3 NeuroSigma
  • 10.4 Atenxia
  • 10.5 Braingaze
  • 10.6 Tali Digital
  • 10.7 Neurotech International
  • 10.8 Sincrolab
  • 10.9 Poppins
  • 10.10 Limbix
  • 10.11 Floreo
  • 10.12 Rethink Autism
  • 10.13 Elemy
  • 10.14 Mightier
  • 10.15 Revibe Technologies

List of Tables

  • Table 1 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Mobile Applications (2024-2032) ($MN)
  • Table 4 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Software Platforms (2024-2032) ($MN)
  • Table 5 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Virtual Reality (VR)-based Therapies (2024-2032) ($MN)
  • Table 6 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Wearable-integrated Solutions (2024-2032) ($MN)
  • Table 7 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Disorder Type (2024-2032) ($MN)
  • Table 8 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Attention Deficit Hyperactivity Disorder (ADHD) (2024-2032) ($MN)
  • Table 9 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Autism Spectrum Disorder (ASD) (2024-2032) ($MN)
  • Table 10 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Dyslexia & Learning Disabilities (2024-2032) ($MN)
  • Table 11 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Other Disorder Types (2024-2032) ($MN)
  • Table 12 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By End User (2024-2032) ($MN)
  • Table 13 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Patients (2024-2032) ($MN)
  • Table 14 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Caregivers (2024-2032) ($MN)
  • Table 15 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 16 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Payers / Insurance Companies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.